Mayo Clinic | Strategic Alliance Partners

October 31, 2019

Shaji K. Kumar, MD, discusses the takeaways from the phase III BELLINI trial which tested venetoclax in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

October 29, 2019

Parminder Singh, MD, discusses the improvement in overall response rates with immunotherapy, targeted therapy, and antibody-drug conjugates in advanced urothelial cancer.

October 25, 2019

Alan H. Bryce, MD, discusses treatment selection in nonmetastatic castration-resistant prostate cancer.

October 24, 2019

Pashtoon M. Kasi, MD, MBBS, MS, discusses the prognostic value of circulating tumor DNA in colorectal cancer.

October 23, 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the rationale to explore the combination of tucatinib and trastuzumab (Herceptin) in patients with HER2-overexpressing metastatic colorectal cancer.

October 22, 2019

Parminder Singh, MD, discusses combination treatments that are being evaluated in localized bladder cancer.

October 15, 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.

October 11, 2019

Tanios S. Bekaii-Saab, MD, discusses the safety profile of the combination of tucatinib and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.

October 05, 2019

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses the rationale to evaluate atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

October 02, 2019

Lewis R. Roberts, MB, ChB, PhD, discusses the past, present, and future of treatment in patients with perihilar and intrahepatic cholangiocarcinoma.  

September 30, 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the implications of the randomized phase III APACT trial evaluating gemcitabine alone versus gemcitabine plus nab-paclitaxel as adjuvant therapy in patients with pancreatic cancer.

September 25, 2019

Matthew P. Goetz, MD, discusses adverse events associated with aromatase inhibitors.

September 24, 2019

Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.

September 05, 2019

Manoj K. Jain, MD, discusses the use of radioligand therapy in prostate cancer.

September 04, 2019

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses research being done with antibody-drug conjugates (ADCs) in advanced bladder cancer.

September 04, 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).

August 29, 2019

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses reasons to explore biosimilars in oncology.

August 23, 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses treatment beyond progression on CDK4/6 inhibitors in hormone receptor (HR)-positive breast cancer.

August 16, 2019

Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the treatment landscape of estrogen receptor (ER)–positive breast cancer and advances made within the last 5 years.

August 02, 2019

Pashtoon M. Kasi, MBBS, MD, MS, hematologist, internist, oncologist, Mayo Clinic, discusses the comparison of circulating tumor DNA tests, tissue, and liquid biopsies, in a study of patients with colorectal cancer.